Skip to main content

Table 2 Cox regression analyses of survival among surrogate molecular subtypes by immunohistochemistry in primary DCIS (n=458), by follow-up period

From: Molecular subtypes in ductal carcinoma in situ of the breast and their relation to prognosis: a population-based cohort study

 

Follow-up period

 

> 3 months – 10 years

 

> 10 years

 

Type of event

Unadjusted HR (95% CI)

Adjusted* HR (95% CI)

Unadjusted HR (95% CI)

Adjusted* HR (95% CI)

Local recurrence ( in situ or invasive)

No. of events: 84

 

No. of events: 17

Luminial A

1.0 (reference)

1.0 (reference)

1.0 (reference)

1.0 (reference)

Luminal B/HER2-

1.39 (0.64-3.01)

1.61 (0.73-3.54)

no events

-

Luminal B/HER2+

1.31 (0.72-2.40)

1.63 (0.84-3.17)

0.78 (0.21-2.89)

1.01 (0.22-4.62)

HER2+/ER-

1.21 (0.62-2.34)

1.77 (0.85-3.68)

0.27 (0.03-2.14)

0.58 (0.06-5.89)

Triple negative

1.37 (0.57-3.28)

1.38 (0.56-3.38)

0.94 (0.12-7.44)

0.78 (0.09-7.22)

Unclassified

0.73 (0.36-1.49)

0.77 (0.38-1.58)

0.95 (0.25-3.60)

1.19 (0.29-4.78)

Invasive or general recurrence

No. of events: 47

 

No. of events: 19

 

Luminial A

1.0

1.0

1.0

1.0

Luminal B/HER2-

2.02 (0.80-5.13)

2.51 (0.97-6.49)

no events

-

Luminal B/HER2+

1.49 (0.68-3.25)

1.97 (0.83-4.67)

0.78 (0.25-2.44)

0.72 (0.21-2.56)

HER2+/ER-

0.71 (0.24-2.12)

0.98 (0.31-3.17)

no events

-

Triple negative

2.24 (0.83-6.06)

1.99 (0.70-5.63)

0.82 (0.11-6.35)

0.63 (0.07-5.48)

Unclassified

0.70 (0.26-1.90)

0.84 (0.31-2.33)

0.54 (0.12-2.42)

0.53 (0.12-2.42)

All events

No. of events: 112

 

No. of events: 28

 

Luminial A

1.0

1.0

1.0

1.0

Luminal B/HER2-

1.24 (0.62-2.46)

1.47 (0.73-2.94)

no events

-

Luminal B/HER2+

1.20 (0.71-2.01)

1.53 (0.87-2.71)

0.40 (0.12-1.37)

0.39 (0.11-1.45)

HER2+/ER-

0.92 (0.49-1.70)

1.28 (0.65-2.52)

0.17 (0.02-1.25)

0.20 (0.03-1.58)

Triple negative

1.30 (0.61-2.75)

1.37 (0.64-2.98)

2.95 (1.07-8.16)

3.21 (1.05-9.83)

Unclassified

0.78 (0.43-1.39)

0.82 (0.45-1.48)

0.85 (0.28-2.58)

1.02 (0.33-3.21)

  1. *Adjusted for age, mode of detection, size, grade, surgery and radiotherapy.